Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Liabilities: 2020-2025

Historic Total Liabilities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $199.5 million.

  • Tarsus Pharmaceuticals' Total Liabilities rose 43.70% to $199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.5 million, marking a year-over-year increase of 43.70%. This contributed to the annual value of $152.5 million for FY2024, which is 122.56% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Total Liabilities stood at $199.5 million for Q3 2025, which was up 22.85% from $162.4 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Total Liabilities peaked at $199.5 million during Q3 2025, and registered a low of $10.7 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $124.6 million (2024), whereas its average is $110.2 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Total Liabilities decreased by 0.51% in 2021 and then soared by 202.44% in 2024.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Total Liabilities stood at $12.2 million in 2021, then spiked by 187.12% to $35.0 million in 2022, then skyrocketed by 95.93% to $68.5 million in 2023, then soared by 122.56% to $152.5 million in 2024, then surged by 43.70% to $199.5 million in 2025.
  • Its Total Liabilities stands at $199.5 million for Q3 2025, versus $162.4 million for Q2 2025 and $158.3 million for Q1 2025.